International Journal of Pharmaceutical Investigation logo
Submit
International Journal of Pharmaceutical InvestigationACADEMIC PUBLISHING
Article

Evaluation of anti‑diabetic activity of AHPL/AYTAB/0513 tablet in streptozotocin induced diabetes in rats

1★, 2, 3★ Corresponding author

  1. 1R & D Center, Ari Healthcare Private Limited, International Biotech Park, HINJEWADI.
  2. 2Padm. Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, INDIA.
  3. 3Ari Healthcare Private Limited, International Biotech Park, Hinjewadi, Pune, Maharashtra, INDIA.

CORRESPONDENCE

Sanjay U Nipanikar

R & D Center, Ari Healthcare Private Limited, International Biotech Park, HINJEWADI.

sanjay.n@arihealthcare.in

Volume 7, Issue 1 · pp. 25-32 · 2017 · DOI: 10.4103/jphi.JPHI_34_16

ABSTRACT

Background: Diabetes is a chronic, progressive disease associated with several complications leading to significant mortality and morbidity. Limitations and drawbacks of the conventional treatment generate need for safer, effective complimentary therapies to prevent complications, and maintain normoglycemic status.Aim and Objectives: The aim of this study is to to evaluate antidiabetic activity of AHPL/AYTAB/0513 tablet alone, oral hypoglycemic agents (OHA[s]), and combination of AHPL/AYTAB/0513 tablet and OHA(s) in streptozotocin‑induced diabetes in rats.Materials and Methods: Totally, ten groups of animals were studied comparatively to evaluate antidiabetic activity of AHPL/AYTAB/0513 tablet, OHA(s), and combination of AHPL/AYTAB/0513 tablet and OHA(s). Blood glucose level (BGL), lipid profile, serum creatinine, serum insulin level, and histopathological characteristics of pancreas were studied to evaluate the efficacy of various formulations. Histopathological examination of kidney and heart was carried out to assess the ability of various formulations in preventing complications of diabetes.Results: There was a significant decrease in mean BGL, serum triglycerides, serum total cholesterol, low‑density lipoprotein (LDL), very LDL, and serum creatinine levels in all formulations groups. Significant increase in mean serum insulin level and high‑density lipoprotein level was observed when compared to diabetic control (DC) group. Recovery of pancreatic beta cells and prevention of damage to heart and kidney cells was significant in all the formulation groups as compared to DC group. None of the formulations tested in nondiabetic rat showed hypoglycemia suggesting safety of all the formulations.Conclusion: AHPL/AYTAB/0513 tablet alone and in combination with OHA(s) can be effectively used in the management of diabetes mellitus. In addition, AHPL/AYTAB/0513 tablet alone and in combination with OHA(s) help in prevention of diabetic complications. As an adjuvant to OHA(s), AHPL/AYTAB/0513 tablet can be more effective.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Nipanikar, S. U., Chitlange, S. S., & Nagore, D. (2017). Evaluation of anti‑diabetic activity of AHPL/AYTAB/0513 tablet in streptozotocin induced diabetes in rats. International Journal of Pharmaceutical Investigation, 7(1), 25-32. https://doi.org/10.4103/jphi.JPHI_34_16

    Copyright and licence

    © 2017 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0